2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA
Notice of Delisting - Jasper Therapeutics, Inc. Fails to Meet Nasdaq Equity R...
Shareholder votes
Other Events
Material Contracts, Completing Asset Acquisition or Sale, Unregistered Sales of Equity Securities, Changes in Board, Management or Compensation, Amendments to Articles of Incorporation or Bylaws, Reg. FD
Announces Merger with Kira Pharmaceuticals
Annual Report to Security Holders
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Q2
Q1
FY 2025
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload
S-8 POS